Optimi Health Jumps to Nasdaq With $15 Million in Fresh Cash — But Can a Company With $99,500 in Revenue Justify a $28 Million Valuation?

Shares surged 8.3% in pre-market to $4.95 as investors continued piling into Optimi Health seven weeks after its Nasdaq debut, even though no new company-specific news triggered the move. The Vancouver-based psychedelic drug maker — which manufactures pharmaceutical-grade psilocybin and MDMA capsules for mental-health therapies — is riding a wave of speculative appetite for newly listed names in the psychedelic sector. Here's what shareholders need to weigh.

The Nasdaq Listing Opened a Door, but the Stock Has Fallen Through It

Optimi priced its oversubscribed offering at US$6.25 per share, selling 2.4 million shares and raising roughly $15 million in gross proceeds . Trading began on May 20, 2026 under the ticker OPTH . At today's $4.95, the stock sits 21% below its IPO price, meaning every investor who bought into the offering is underwater. The company's market cap hovers around $28–32 million with approximately 5.6 million shares outstanding .

Revenue Is Barely a Rounding Error

Optimi generated just $99,500 in drug-product revenue in the six months ended March 31, 2026, down from $293,941 a year earlier . That puts the price-to-sales ratio near 70x — a valuation that prices in massive future growth that hasn't materialized. The company held only $106,711 in cash at quarter-end and carried $9.8 million in current liabilities , though the subsequent Nasdaq raise injects critical working capital.

The Regulatory Bet Is Real — But Distant

Optimi began supplying psilocybin capsules to Australian clinics under a government prescriber program in 2024 for PTSD and treatment-resistant depression . A U.S. executive order in April 2026 flagged psychedelic compounds for accelerated review , potentially broadening the market. But Optimi's own filings note "significant doubt about going concern" , meaning auditors flagged a real risk the company could run out of money before its market arrives.

The $15 Million Buys Time, Not Certainty

Proceeds are earmarked for production scaling, U.S. distribution expansion, and working capital . Net proceeds came to roughly C$18.4 million after fees — enough runway for perhaps two years at current burn rates. But investors are essentially buying a bet that psychedelic regulations will open fast enough to generate meaningful sales before the cash runs dry. Today's pop is sentiment, not substance.